ArticleNeuropharmacology2018

The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.

Andrew J Flores et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.